Nta Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth -38.28%
- Profit Growth 1283.28%
- Ebitda 71.79%
- Net Worth 5.94%
- Total Assets 5.13%
About Nta Pharma
Nta Pharma Private Limited (NPPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 July 2012 and has a history of 12 years and seven months. Its registered office is in Kheda, Gujarat, India.
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Karan Virji, Kanubhai Patel, Sunil Joshi, and One other member serve as directors at the Company.
Company Details
- Location
Kheda, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239GJ2012PTC071235
- Company No.
071235
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Jul 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Nta Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karan Virji  | Director | 20-Jul-2012 | Current |
| Kanubhai Patel | Director | 16-May-2019 | Current |
| Sunil Joshi | Director | 16-May-2019 | Current |
| Kartik Laijawala | Director | 20-Jul-2012 | Current |
Financial Performance of Nta Pharma.
Nta Pharma Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 38.28% decrease. The company also saw a substantial improvement in profitability, with a 1283.28% increase in profit. The company's net worth moved up by a moderate rise of 5.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nta Pharma?
In 2019, Nta Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nico Orgo Marketing Private LimitedKaran Virji and Kartik Laijawala are mutual person
Nico Orgo Biotech Private LimitedKaran Virji and Kartik Laijawala are mutual person
Thasra Ginning And Pressing Company LimitedKaran Virji is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Nta Pharma?
Unlock and access historical data on people associated with Nta Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nta Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nta Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.